Mason Capital Management, holding 2.1% of Grifols (GRFS) Class A shares, sent a critical letter to the Board highlighting corporate governance failures and value destruction. The letter opposes a rumored Brookfield transaction that allegedly undervalues the company. Mason criticizes the Board's history of poor capital allocation, citing €4.5 billion in debt-financed acquisitions since 2014 that only added €136 million in EBITDA. The investor points out conflicts of interest, particularly regarding board member Tomas Daga and Osborne Clarke Spain's involvement in multiple transactions. Mason calls for immediate implementation of corporate governance reforms and suggests the company is worth €20+ per share versus the rumored €12 Brookfield offer.
Synthetic Biologics (NYSE American: SYN) announced promising preclinical results regarding the combination of VCN-01, an oncolytic adenovirus, and topotecan for treating refractory retinoblastoma. Data presented at the SIOP 2022 Congress indicates that this combination significantly enhances VCN-01’s infection and replication in retinoblastoma cells and improves ocular survival in preclinical models. A clinical study is anticipated to commence in the second half of 2023, underscoring the therapeutic potential of this novel approach in addressing high unmet needs in pediatric oncology.
Synthetic Biologics (NYSE American: SYN) has reported a favorable recommendation from the Data and Safety Monitoring Committee (DSMC) to proceed to Cohort 2 of its Phase 1b/2a clinical trial for SYN-004 (ribaxamase). This trial aims to prevent acute graft-versus-host disease (aGVHD) in hematopoietic cell transplant recipients. Cohort 1 enrolled 19 patients, with no adverse events linked to the study drug. The next phase will assess SYN-004 with piperacillin/tazobactam, with enrollment expected to continue through Q4 2022, highlighting the potential therapeutic benefits of SYN-004 for vulnerable patient populations.
Synthetic Biologics (NYSE American: SYN) announced initial data from a Phase 1 study of VCN-01 with durvalumab for recurrent/metastatic squamous cell carcinoma of the head and neck. The data, presented at the ESMO Congress, indicates an acceptable safety profile with common treatment-related adverse events including pyrexia and flu-like symptoms. Biological activity showed sustained blood levels and increased CD8 T cells. The company plans to initiate a Phase 2 study for metastatic pancreatic adenocarcinoma in Q4 2022 and a Phase 2/3 study for retinoblastoma in H2 2023.
Synthetic Biologics, Inc. (NYSE American: SYN) reported its Q2 2022 financial results, revealing a cash balance of $53.5 million as of August 1, 2022, following a $3 million financing. The company focuses on its novel oncolytic adenovirus (OV) platform, prioritizing oncology programs to extend operations into Q1 2024. Key upcoming milestones include initiating Phase 2 studies for pancreatic adenocarcinoma and retinoblastoma. Q2 expenses rose, with $3.5 million in R&D costs, reflecting the integration of VCN-01 following the acquisition of VCN Biosciences.
Synthetic Biologics (NYSE American: SYN) announced its participation in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, taking place virtually and in New York City from August 8-9, 2022. The company is focused on developing therapeutics for diseases with high unmet needs. It recently acquired VCN Biosciences, enhancing its capabilities in cancer treatment through its lead candidate VCN-01. Other key products include SYN-004, aimed at preventing microbiome damage, and SYN-020, a formulation of intestinal alkaline phosphatase.
Synthetic Biologics, Inc. (NYSE American: SYN) announced a conference call on August 11, 2022, at 8:30 a.m. ET to discuss its financial results for Q2 2022 and provide a corporate update. The call is accessible by phone or through the company's website. The recent acquisition of VCN Biosciences, S.L. enhances SYN's portfolio with a new oncolytic adenovirus platform aimed at effectively targeting tumor cells, which complements SYN's existing therapeutics like SYN-004 and SYN-020 designed to address gastrointestinal health issues and antimicrobial resistance.
Synthetic Biologics, a clinical-stage company, announced a private placement of 275,000 shares of Series C and 100,000 shares of Series D convertible preferred stock at $8.00 each, amounting to gross proceeds of $3 million. The shares are convertible into common stock at an initial price of $1.22, contingent upon shareholder approval for increasing authorized shares from 20 million to 350 million. The offering closed on July 29, 2022, with A.G.P./Alliance Global Partners serving as the exclusive financial advisor. Registration for the resale of common stock is expected within 45 days.
Synthetic Biologics, Inc. (NYSE American: SYN) announced a 1-for-10 reverse stock split effective July 25, 2022, to comply with NYSE American price requirements. The number of outstanding common shares will decrease from 158.4 million to 15.8 million. No fractional shares will be issued, and shareholders will automatically round up to the nearest whole share. The split aims to enhance the share price and maintain listing compliance, following the Board's authorization on July 11, 2022. The company continues to develop therapeutics in oncology and gastrointestinal health.
Synthetic Biologics (SYN) reported positive updates on its oncology pipeline, including promising clinical data for VCN-01 and SYN-020. A peer-reviewed publication highlighted VCN-01’s feasibility and safety, complemented by an upcoming presentation on VCN-11. Phase 1 trial data for SYN-020 indicated a favorable safety profile. The company formed a Scientific Advisory Board to bolster its clinical development strategy. As of March 31, 2022, SYN held $56.7 million in cash, expected to fund operations through 2023.